{"filings":[{"id":863477,"accession_number":"0001437749-26-019576","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2026-06-04T21:20:09+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"NRx Pharmaceuticals closes $22.3M public offering of common stock at $3.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 5,714,286 shares at $3.50; underwriters' option for 857,142 shares exercised, gross proceeds $22.3M.","Net proceeds estimated ~$21.6M after underwriting discounts and expenses; funds working capital and growth.","BTIG acted as lead bookrunner; Lucid Capital Markets as joint bookrunner.","Offering led by B Group Capital, with participation from Columbia Threadneedle, Corbets Capital, Venture 76, and Mossrock Capital.","Shares issued under effective S-3 shelf (No. 333-288205); closed June 4, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":808756,"accession_number":"0001437749-26-019196","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2026-06-02T21:30:08+00:00","items":["8.01","9.01"],"status":"ready","headline":"NRx Pharmaceuticals proposes public offering of common stock; terms not set","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Intends to offer common stock in underwritten public offering; no size or price disclosed.","Underwriter granted 30-day option to purchase up to 15% additional shares on same terms.","BTIG is lead bookrunner; Lucid Capital Markets joint bookrunner for the offering.","Net proceeds to be used for working capital and general corporate purposes.","Offering under effective shelf registration statement (File No. 333-288205) declared effective Dec 22, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107719,"accession_number":"0001437749-26-009611","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"NRx Pharmaceuticals stockholders approve increased evergreen share reserve cap at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholder approved Amendment No. 1 to 2021 Omnibus Incentive Plan, effective March 23, 2026.","New annual share increase is lesser of 3,187,234 shares, 5% of outstanding, or Board-determined amount.","Class I directors Chaim Hurvitz and Michael Taylor re-elected with 9.86M and 9.89M For votes.","Appointment of Weinberg & Company as auditor ratified with 17.35M For (98.5% of votes cast).","Non-binding advisory vote on named executive officer compensation passed with 9.97M For."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107718,"accession_number":"0001437749-26-004246","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NRx Pharma announces FDA path to NDA for NRX-100 with broader TRD+suicidality indication","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA meeting provided clear path to submit NDA for NRX-100 under Fast Track; endpoints support full approval rather than Accelerated Approval.","Indication expanded to treatment-resistant depression with suicidality, targeting over 10 million TRD patients.","Real World Evidence from 65,000+ patient dataset to be used as confirmatory data; FDA to review analysis protocol.","NDA submission planned for Q2 2026; PDUFA date anticipated in 2026.","ANDA for generic ketamine remains under review with decision expected Summer 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107717,"accession_number":"0001437749-26-004245","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NRx Pharmaceuticals files $20M ATM offering for common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement for up to $20M of common stock via ATM with H.C. Wainwright & Co.","Shares to be issued under S-3 registration statement declared effective December 22, 2025.","Legal opinion from Cozen O'Connor on share validity filed as Exhibit 5.1.","No specific sales, pricing, or use of proceeds disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107716,"accession_number":"0001437749-26-002682","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"NRx Pharmaceuticals appoints Joseph M. Casper as COO; base salary $250,000 plus options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph M. Casper appointed Chief Operating Officer effective January 27, 2026.","Casper has 35 years of healthcare experience including Deloitte, Kaiser Permanente, and Anthem.","Annual base salary of $250,000 with a bonus of 25% subject to milestones with CEO.","Granted 100,000 options: 33.3% vest June 1, 2026, 33.3% Dec 1, 2026, 33.3% Dec 1, 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107715,"accession_number":"0001437749-26-001455","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2026-01-16T23:59:59+00:00","items":["3.01","7.01","8.01","9.01"],"status":"ready","headline":"NRx Pharmaceuticals Receives Nasdaq Non-Compliance Notice for Delayed Annual Meeting; Sets 2025 Meeting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Jan 12, 2026 for failing to hold annual meeting within 12 months of fiscal year end.","Company has 45 days to submit a plan to regain compliance; Nasdaq may grant exception until June 29, 2026.","Annual meeting set for March 23, 2026 with record date of February 12, 2026.","Stock continues trading under symbol NRXP; non-compliance indicator will be broadcast after five business days.","Stockholder proposals or director nominations must be received by January 26, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124087,"accession_number":"0001437749-25-038835","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NRx Pharmaceuticals eliminates all balance sheet debt by converting $5.4M to equity","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repaid remaining $5.4M debt to Anson Funds via equity conversion of common stock; no warrants or repricing mechanisms.","Original Anson loan was $16.2M; Company expects Dec 31 balance sheet to reflect zero convertible debt.","Debt-free capital structure positions NRx for accelerated growth with potential 2026 drug approvals and clinic expansions.","Press release dated Dec 2, 2025; Debt Cancellation Agreement executed Dec 29, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124086,"accession_number":"0001437749-25-036452","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"NRx Pharmaceuticals replaces auditor Salberg & Company with Weinberg & Company","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Engaged Weinberg & Company as independent auditor for FY ending Dec 31, 2025, effective Nov 20, 2025.","Dismissed Salberg & Company on Nov 24, 2025; no disagreements or reportable events in prior years.","Salberg's prior audit opinions contained a going-concern explanatory paragraph but were otherwise unqualified.","Weinberg had previously audited Dura Medical LLC, a subsidiary acquired by Hope Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124084,"accession_number":"0001437749-25-036005","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K/A","filed_at":"2025-11-21T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"NRx Pharmaceuticals amends 8-K to provide acquired Dura Medical's FY2024 financials","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of Dura Medical closed September 8, 2025; this amendment provides required financials.","Dura Medical FY2024: net patient revenue $3.26M, net income $505K, total assets $1.37M.","Dura Medical for six months ended June 30, 2025 (unaudited) also provided.","Pro forma combined financials filed; reflects impact of acquisition on NRx statements.","Audited by Weinberg & Company; no material adjustments noted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124085,"accession_number":"0001437749-25-031637","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"NRx subsidiary HOPE Therapeutics acquires minority interest in Cohen & Associates; Dr. Cohen named Medical Director","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["HOPE Therapeutics acquired strategic minority interest in Rebecca S. Cohen, MD, LLC (Cohen & Associates) of Sarasota, FL, effective Oct 17, 2025.","Dr. Rebecca Cohen appointed Medical Director of HOPE Therapeutics, overseeing medical standards in Florida locations.","Cohen & Associates offers TMS, ketamine, and medication management for depression, PTSD, and CNS disorders.","Immediate expansion planned in Western Florida and Palm Beach.","Acquisition expected to be accretive to HOPE Therapeutics revenue and EBITDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140754,"accession_number":"0001437749-25-029907","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA grants Suitability Petition for NRx's preservative-free ketamine, enabling ANDA re-filing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved Suitability Petition for proposed strength of NRx's single-patient, preservative-free ketamine (KETAFREE™).","Currently marketed ketamine uses multi-dose vials with toxic preservative Benzethonium Chloride; KETAFREE™ is preservative-free.","Suitability Petition grant enables immediate re-filing of Abbreviated New Drug Application (ANDA) for KETAFREE™.","NRx estimates total ketamine market at $750M; product aligns with FDA/HHS policy on removing toxic preservatives.","NRx CEO noted rapid FDA response after company attended listening session with FDA Commissioner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140753,"accession_number":"0001437749-25-028949","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"NRx subsidiary HOPE Therapeutics completes acquisition of Dura Medical","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Dura Medical is revenue generating and EBITDA positive; operates clinics in Naples and Ft. Myers.","Offers ketamine therapy, TMS, Spravato, stellate ganglion blocks for depression and PTSD.","Participates in VA Community Cares Network; founder Stephen Durand appointed Director of Florida Clinic Operations.","Combined with pending acquisitions to provide coverage at more than 8 locations on Florida's West Coast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140752,"accession_number":"0001437749-25-028567","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NRx Pharmaceuticals raises $8.8M, announces HOPE Therapeutics launch and Rockefeller advisory role","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $8.8M gross from experienced biotech investors via common stock offering; no warrants or variable rate features.","HOPE Therapeutics subsidiary to launch in September 2025 with flagship location in Palm Beach, FL.","Clinics will combine ketamine, transcranial magnetic stimulation, hyperbaric oxygen for suicidal depression, PTSD, TBI.","Matthew Rockefeller joins HOPE Therapeutics Advisory Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140751,"accession_number":"0001437749-25-027256","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"NRx Pharma raises $6.5M, Q2 operating loss improves to $3.7M, FDA expands Fast Track for NRX-100","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Registered direct offering of 3,959,999 shares at $1.65/sh raises ~$6.5M; one-year lockup, no warrants.","Q2 net loss $17.6M (vs $7.9M) on non-cash fair value changes; operating loss narrows to $3.7M (vs $7.1M).","FDA expanded Fast Track for NRX-100 to all depression types, addressing 13M Americans annually.","Cash balance $2.9M at June 30; with new capital expects to fund operations into 2026.","HOPE Therapeutics acquires Dura Medical, signs LOIs for NeuroSpa and Cohen and Associates; debt financing $7.8M approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140750,"accession_number":"0001437749-25-027059","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA Fast Track for NRX-100 in suicidal depression; ANDA filing deficiency noted","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Fast Track designation for NRX-100 (IV ketamine) to treat suicidal ideation in depression, including bipolar depression.","Addressable population expands to 13M Americans considering suicide/year, 10x larger than prior 2017 designation.","Company also received FDA letter on August 13 citing missing batch records and 6% inactive ingredient difference in ANDA for NRX-100; expects to remedy and resubmit.","Fast Track enables potential CNPV/accelerated approval, rolling review, and enhanced FDA communication.","NRX-100 is preservative-free ketamine; company citizen petition to remove BZT from IV ketamine products."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158494,"accession_number":"0001437749-25-019803","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NRx Pharma files ANDA for preservative-free IV ketamine; market at $750M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed ANDA for NRX-100 (preservative-free IV ketamine) with FDA; seeks priority review due to drug shortage.","Ketamine market currently $750M, projected to reach $3.35B globally by 2034.","Plans citizen petition to remove benzethonium chloride from all IV ketamine products.","Complements ongoing NDA for suicidal depression; PDUFA target late 2025; FDA waived $4.3M fee.","Patent protection sought through 2045; Fast Track designation previously granted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158493,"accession_number":"0001437749-25-018000","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"NRx Pharmaceuticals reports Q1 net loss of $5.5M, advances NDA filings and HOPE clinic acquisitions","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $5.5M for Q1 2025 from $6.5M in Q1 2024; operating loss $3.8M vs $6.0M.","Cash & cash equivalents $5.5M at March 31, 2025; company expects sufficient runway through end of 2025.","NDA for NRX-100 (IV ketamine) filing on track for Q2 2025; FDA waived $4.3M filing fee; U.S. patent application filed.","HOPE Therapeutics signed $7.8M debt term sheet with Universal Capital and $2.5M strategic investment for clinic acquisitions; initial clinics have ~$15M pro-forma revenue.","NRX-101 NDA submission for suicidal bipolar depression on track for 2025; anticipates PDUFA before year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158492,"accession_number":"0001437749-25-016272","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NRx Pharmaceuticals subsidiary HOPE signs definitive agreement to acquire Kadima Neuropsychiatry Institute","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Kadima is a profitable interventional psychiatry clinic in La Jolla, CA, expected to serve as clinical model for HOPE network.","Dr. David Feifel, Kadima founder, to join HOPE as Chief Medical Innovation Officer upon closing.","Acquisition expected to be accretive to revenue and EBITDA for NRx and HOPE.","Closing subject to customary conditions and finalization of financing; further details to follow.","Kadima is a leading investigative site for CNS and psychedelic research, including ketamine and TMS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158491,"accession_number":"0001437749-25-012303","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NRx Pharmaceuticals boosts ATM offering capacity to $20M; previously sold $1.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Maximum aggregate offering price increased to $20,000,000 under ATM agreement with H.C. Wainwright & Co.","Approximately $1.8 million in common stock sold prior to the increase.","Prospectus supplement filed on April 17, 2025 to register the additional shares.","Legal opinion on share validity filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176877,"accession_number":"0001437749-25-008777","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"NRx Pharma posts FY2024 operating loss of $18.5M; NDA filings for ketamine and bipolar drug anticipated in 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 operating loss $2.4M, down 45% YoY; FY2024 operating loss $18.5M vs $27.8M in 2023.","Received non-binding terms for NRX-100 license with >$300M milestones plus double-digit royalties.","Initiated NDA for NRX-100 (IV ketamine) and plans NDA for NRX-101 (bipolar depression); both target PDUFA dates before Dec 31, 2025.","HOPE Therapeutics signed LOIs to acquire three precision psychiatry centers; negotiating for six more; BTIG engaged as advisor.","Cash $1.4M at Dec 31, 2024; raised $8.5M in Jan 2025; management expects sufficient cash through end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176876,"accession_number":"0001437749-25-002610","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"NRx Pharma secures $27M financing for subsidiary Hope Therapeutics clinic rollup","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 732,600 shares at $2.73/share for $2M immediate funding.","Investor committed to $25M in Hope Series A Preferred convertible into 1/3 equity, 15% dividend, non-callable for 2 years.","First $6.75M tranche of Hope investment due by Feb 7, 2025; remaining $18.25M by Apr 1, 2025.","Funds to acquire Kadima Neuropsychiatry and start nationwide interventional psychiatry clinic rollup.","Company anticipates pro-forma revenue of ~$100M by end of 2025 using bank leverage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176875,"accession_number":"0001437749-25-002160","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"NRx Pharmaceuticals secures $8.9M financing from Anson Funds to support NDA filings, operations into 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $5.435M senior secured notes (net proceeds ~$5M) and warrants for 862,699 shares at $3.78 strike; registered direct offering of 1,215,278 shares at $2.88/share.","Total gross proceeds of ~$8.9M from Anson Funds; notes carry 8% OID, 6% interest, 15-month maturity, convertible at $3.78/share subject to reset.","Proceeds will fund NRX-100 and NRX-101 NDA filings, HOPE Therapeutics launch, and potential pipeline additions; expected to fund operations into 2026.","Company believes combined with projected sales and non-dilutive funding it can reach profitability; includes waiver of certain investor rights through March 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176874,"accession_number":"0001437749-25-001569","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2025-01-22T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"NRx regains Nasdaq compliance; appoints Mike Taylor director amid $25M HOPE investment term sheet","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq notice on Jan 17 that it regained MVLS compliance; requirement met on Jan 16 after 10 consecutive trading days above $35M.","Appointed Mike Taylor as Class I director, filling vacancy from Janet Rehnquist resignation, effective Jan 15.","Taylor designated by JGS Holdings per term sheet for $25M in HOPE Series A Preferred convertible into 1/3 of HOPE equity and $2M for 730k NRXP shares.","Nasdaq closed the matter, removing delisting risk from the Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176873,"accession_number":"0001437749-25-001113","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"NRx Pharma board member Janet Rehnquist resigns; JGS Holdings gets board designation right","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Janet Rehnquist resigned from the Board effective January 7, 2025; no disagreement with Company.","Term sheet with JGS Holdings LLC (Sauer Nunes) grants right to designate a Board member.","Management currently considering nominees from JGS Holdings for appointment to the Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176872,"accession_number":"0001437749-25-000801","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"NRXP subsidiary HOPE signs $27M term sheet with Smith & Sauer; $25M preferred equity, $2M common","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Smith & Sauer to purchase $25M Series A Preferred in HOPE convertible into 1/3 of fully diluted equity, with 15% dividend.","$2M purchase of NRXP common at $2.75/share (above recent close); investor also buys 500K shares from existing holders at $2.75.","Warrants for 3M NRXP shares at $3.00/sh with 24-month term, plus royalties on product sales up to $250M cumulative return.","Smith & Sauer gets board seats at both HOPE and NRXP; funding to support clinic acquisitions and NRX-100/NRX-101 development.","Closing subject to definitive agreements and standard conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193678,"accession_number":"0001437749-24-035806","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"NRx Pharmaceuticals appoints Michael Abrams as permanent CFO, base salary $325,000","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Abrams appointed CFO effective Nov 18, 2024, succeeding interim CFO Richard Narido.","Base salary $325,000; initially 50% until Qualified Financing or Feb 1, 2025.","Granted 50,000 stock options under 2021 Omnibus Incentive Plan, vesting over three years.","Abrams previously CFO at Arch Therapeutics, RiseIT Solutions, and FitLife Brands.","Employment agreement includes non-compete, non-solicitation, and severance provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193677,"accession_number":"0001437749-24-035521","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"NRx Q3 net operating loss down 74% to $1.6M; on track for NDA filings by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net operating loss $1.6M in Q3 2024 vs $6.1M in Q3 2023; nine-month net loss $16.1M vs $25.8M.","Cash $1.6M at Sep 30; closed $5.4M second tranche from Anson Funds post-quarter; $10.8M total convertible debt.","Expects to file NDAs for NRX-100 (IV ketamine) and NRX-101 (bipolar depression) by end of 2024, with 2025 PDUFA dates.","HOPE Therapeutics signed two non-binding LOIs to acquire Interventional Psychiatry Clinics; first revenue forecast by year-end 2024.","Retired Streeterville debt at substantial discount; litigation settled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193676,"accession_number":"0001437749-24-032705","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NRx subsidiary HOPE signs non-binding LOI to acquire Florida Interventional Psychiatry Clinics","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["HOPE Therapeutics, NRx subsidiary, signs LOI for first Interventional Psychiatry Clinics in Florida.","Clinics are revenue generating and EBITDA positive; acquisition expected to be immediately accretive.","Acquisition subject to definitive documentation and receipt of adequate financing.","Clinics will form foundation for HOPE's growth in Florida; founders to help optimize additional acquisitions.","NRx and HOPE aim to establish a model for CNS care clinics nationwide."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193675,"accession_number":"0001437749-24-031268","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"NRx Pharma closes $5.435M second tranche of secured notes; cancels third tranche","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["On Oct 10, 2024, closed second tranche: $5.435M principal amount of Senior Secured Convertible Notes (purchase price ~$5.0M) and warrants for 1,846,128 shares.","Proceeds to repay existing variable priced convertible notes and for general working capital.","Conversion price is lower of $1.7664 or 92% of lowest 7-day VWAP prior to conversion date.","Company and investor mutually agreed not to proceed with the third $5.435M tranche.","Placement agent EF Hutton receives 7% cash fee and up to $50,000 expense reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193674,"accession_number":"0001437749-24-031133","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2024-10-11T23:59:59+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"NRx CEO resigns; Chairman Javitt takes interim CEO; shareholders approve reverse split","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Stephen Willard resigns effective Oct 7, 2024; Chairman Jonathan Javitt appointed interim CEO.","Stockholders approved reverse stock split authorization (1:2 to 1:5) at board's discretion within one year.","Stockholders approved issuance of shares upon redemption of convertible note and warrants to institutional investors.","Company signed LOI to acquire an interventional psychiatry clinic; targeting $25M+ initial HOPE Therapeutics business and $100M+ revenue by next year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209990,"accession_number":"0001437749-24-027383","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2024-08-20T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"NRx Pharmaceuticals CEO Stephen Willard recommends new CEO with commercial pharma experience; search initiated","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen Willard, CEO of NRx Pharmaceuticals, recommended that the company's shareholders would be best served by a CEO with commercial pharmaceutical experience, particularly drug launch experience.","The company has initiated a search for a new CEO possessing the desired qualifications; Mr. Willard will continue as CEO during the search.","Mr. Willard stated his recommendation is not the result of any disagreement regarding the company's operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209989,"accession_number":"0001437749-24-026908","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NRx Pharma narrows Q2 net loss to $7.9M; secures $10.8–16.3M convertible debt for NDAs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $7.9M vs $8.7M YoY; six-month net loss $14.4M vs $19.8M.","Secured $10.8–16.3M convertible debt from Anson Funds; retired Streeterville debt at litigation discount.","Plans to file NDAs for NRX-100 (IV ketamine) and NRX-101 for bipolar depression in Q4 2024.","HOPE Therapeutics audit complete; spinout SEC filing planned this quarter.","Cash $1.9M at June 30; new funding expected to support filings and operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209988,"accession_number":"0001437749-24-026888","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["1.01","2.03","3.02","5.03","8.01","9.01"],"status":"ready","headline":"NRx Pharmaceuticals secures up to $16M senior secured debt from Anson Funds; settles Streeterville claims","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Up to $16.3M principal in three tranches; first tranche $5.435M principal at $5M purchase price.","Notes convertible at lower of $2.4168 or 92% of lowest VWAP; 6% interest, 15-month maturity.","Warrants for 50% of principal/VWAP, 5-year term, exercise at $2.4168 with potential adjustments.","Proceeds to fund 2024 NDA filings for NRX-100 (ketamine) and NRX-101; retire Streeterville debt.","Streeterville settlement: $2.5M at closing plus $3.05M within 60 days; all claims released."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209987,"accession_number":"0001437749-24-026107","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["3.01","8.01"],"status":"ready","headline":"NRx Pharma receives Nasdaq MVLS deficiency notice; must regain compliance by Feb 3, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified NRx on Aug 6 that MVLS was below $35M minimum from June 14 to Aug 5, 2024.","Company has 180 days (until Feb 3, 2025) to achieve MVLS >= $35M for 10 consecutive days.","Failure to regain compliance may result in delisting; Company can appeal but no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228191,"accession_number":"0001104659-24-075722","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["1.02","8.01"],"status":"ready","headline":"Alvogen terminates NRX-101 pact; NRx eyes accelerated FDA filing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Alvogen terminated exclusive development and license agreement for NRX-101 effective June 21, 2024.","Alvogen claims $4,502,705 in advanced amounts; parties to negotiate royalty within 30 days.","NRx plans Accelerated Approval filing this year for suicidal bipolar depression, citing trial data.","Company continues NDA submission for intravenous ketamine (NRX-100) in 2024.","NRx estimates $3.7B addressable market for NRX-101 in high-risk patients without viable alternatives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228190,"accession_number":"0001558370-24-009369","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"NRx Pharmaceuticals appoints Dr. Dennis McBride to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Dennis McBride appointed to Board, effective June 13, 2024.","Bringing neuroscience, IT, and medical technology expertise from DARPA, Navy, and academia.","Serves as research professor at Virginia Tech; former Director of Acquisition and Innovation Research Center for DoD.","Has experience in CNS-focused digital therapeutics with NRx founders.","No related party transactions or arrangements were disclosed in connection with the appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228189,"accession_number":"0001104659-24-064675","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NRx Pharmaceuticals underwriters exercise overallotment, purchase 91,050 shares at $3.30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriters exercised option to buy 91,050 additional shares at $3.30 per share from previously announced offering.","Gross proceeds from overallotment approximately $300,465; closed May 23, 2024.","Overallotment exercise completed; shares issued at same price as initial public offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228188,"accession_number":"0001558370-24-008337","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"NRx Pharma Q1 net loss narrows to $6.5M; signs $7.5M debt term sheet to replace toxic debt","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss improved 41% YoY to $6.5M, from $11.0M; R&D spend down to $1.7M.","Cash and equivalents $1.3M as of March 31, 2024; additional $3.3M from equity post-quarter.","Signed non-binding term sheet for $7.5M debt to replace toxic debt, with potential total up to $30M.","Plans to file NDA for NRX-101 in bipolar depression with akathisia risk and for IV ketamine (HTX-100) by July 2024.","Hope Therapeutics spinout planned; term sheets received from anchor investors for $60M investment."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228187,"accession_number":"0001104659-24-055041","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["2.04","8.01","9.01"],"status":"ready","headline":"NRx receives default notice on $6.5M note; reports promising NRX-101 trial data vs lurasidone","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Streeterville Capital alleges default on $11.02M convertible note; demands acceleration and repayment of at least $6,537,027.","Company disputes the claim, says spin-off of Hope Therapeutics is not a Fundamental Transaction, and will defend vigorously.","Phase 2b/3 trial: NRX-101 showed 33% advantage in sustained remission of suicidality vs lurasidone (not statistically significant at this sample size).","NRX-101 showed 75% advantage in relief from akathisia (P=0.076), a side effect linked to suicide; both signals met promising zone criteria.","Company plans 300-patient registrational trial; believes NRX-101 could be the first oral antidepressant to reduce suicide risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228186,"accession_number":"0001104659-24-049529","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2024-04-19T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"NRx Pharmaceuticals prices $2.0M public offering of common stock at $3.30 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwritten public offering of 607,000 shares at $3.30/share; gross proceeds ~$2.0M before expenses.","Underwriters granted 45-day option for up to 91,050 additional shares at same price to cover over-allotments.","Company will issue to representative EF Hutton a warrant to purchase up to 30,350 shares (5% of shares sold) at $3.63/share.","Net proceeds to be used for working capital, general corporate purposes, and potential repayment of Streeterville Capital note.","Offering closed on April 19, 2024; shares sold under existing effective shelf registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228185,"accession_number":"0001104659-24-047368","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2024-04-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"NRx Pharmaceuticals increases ATM offering to $4.85M after $1M already sold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Maximum aggregate offering price raised to $4,852,909 under existing August 2023 ATM agreement with H.C. Wainwright.","Prior to this filing, $1.0 million in common stock had been sold under the same agreement.","Prospectus supplement filed April 15, 2024 to register the additional shares.","No specific use of proceeds disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228184,"accession_number":"0001558370-24-004570","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NRx Pharma 2023 net loss $30.2M; expects top-line data this month for NRX-101 TRBD trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for full-year 2023: $30.2M vs $39.8M in 2022; Q4 2023 loss $4.3M vs $10.2M in Q4 2022.","Cash $4.6M at Dec 31, 2023; added $8M in Q1 2024 via equity sales and $5.1M milestone from Alvogen/Lotus.","Expects top-line data in April 2024 from Phase 2b/3 trial of NRX-101 in TRBD; achieved 94% rater concordance.","Plans to spin out HOPE Therapeutics for IV Ketamine; NDA filing expected by June 2024; term sheets for $60M investment.","Reduced G&A expenses 50% YoY to $14.2M in 2023 from $27.3M; corporate overhead decreased by half."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246944,"accession_number":"0001104659-24-040608","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"NRx Pharmaceuticals to effect 1-for-10 reverse stock split effective April 1, 2024 to maintain Nasdaq listing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1:10 ratio; shares outstanding reduced from ~95.7M to ~9.57M.","Effective at 4:30 p.m. ET on April 1, 2024; trading on split-adjusted basis begins April 2, 2024 under symbol NRXP.","Fractional shares rounded up to nearest whole share; par value unchanged.","Chairman cites upcoming clinical trial readouts, planned NDA filing, and dividend of HOPE Therapeutics shares.","CUSIP changes to 629444209; stockholders need not exchange certificates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246943,"accession_number":"0001104659-24-037389","cik":1719406,"company_name":"NRX Pharmaceuticals, Inc.","ticker":"NRXP","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"NRx Pharmaceuticals shareholders approve reverse stock split proposal with 94.4% support","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["94.4% (53,597,974) of votes cast at March 21, 2024 special meeting favor reverse split.","Board authorized to effect split at ratio of 1-for-2 to 1-for-15 within one year.","61.4% (56,781,354) of eligible shares voted despite internet campaign to suppress vote.","Company expects to share annual report on March 28 and update investors on progress."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":155060085.2436195,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}